Current and future treatments of pulmonary arterial hypertension.

Clicks: 336
ID: 93060
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #11 of 36 articles by views in british journal of pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin and nitric oxide pathways have significantly improved outcomes. However, for the vast majority of patients, PAH remains a life limiting illness with no prospect of cure. PAH is characterized by pulmonary vascular remodelling. Current research focusses on targeting the underlying pathways of aberrant proliferation, migration and apoptosis. Despite success in preclinical models, using a plethora of novel approaches targeting cellular GPCRs, ion channels, metabolism, epigenetics, growth factor receptors, transcription factors and inflammation, successful transfer to human disease with positive outcomes in clinical trials is limited. This review provides an overview of novel targets addressed by clinical trials and gives an outlook on novel preclinical perspectives in PAH.
Reference Key
sommer2020currentbritish Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sommer, Natascha;Ghofrani, Ardeschir;Pak, Oleg;Bonnet, Sebastien;Provencher, Steve;Sitbon, Olivier;Rosenkranz, Stephan;Hoeper, Marius M;Kiely, David G;
Journal british journal of pharmacology
Year 2020
DOI
10.1111/bph.15016
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.